Showing results (161-170 of 400) with videos related to

Sort By:
Pageof 40
Annals of Surgical Oncology|July 2, 2026
Neoadjuvant Chemotherapy in Resectable Colon Cancer: Evidence, Controversies, and an Implementation Roadmap for 2026Lorenzo Dottorini, Matteo Viti, Marcella Arru, et al.
Therapeutics and Clinical Risk Management|March 25, 2008
Optimizing use of opiates in the management of cancer painMario Mandalà, Cecilia Moro, Roberto Labianca, et al.
Cancer Immunology, Immunotherapy : CII|November 10, 2020
Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 yearsFausto Petrelli, Alessandro Inno, Antonio Ghidini, et al.
Lung Cancer (Amsterdam, Netherlands)|September 26, 2025
An umbrella review of meta-analyses on smoking cessation and cancer survival: a brief reportFausto Petrelli, Antonio Ghidini, Mauro Rossitto, et al.
Hematology (Amsterdam, Netherlands)|June 16, 2001
Growth Factors: Thrombopoietic Property of the Pineal Hormone MelatoninPAOLO Lissoni, MARIO Mandala, FAUSTO Rossini, et al.
Journal of Geriatric Oncology|April 18, 2020
Efficacy of Eribulin mesylate in older patients with breast cancer: A pooled analysis of clinical trial and real-world dataRebecca Pedersini, Pierluigi di Mauro, Vito Amoroso, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 22, 2019
Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysisFausto Petrelli, Antonio Ghidini, Martina Torchio, et al.
Current Oncology Reports|July 6, 2026
Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant SettingsFausto Petrelli, Lara Colombo Zefinetti, Andrea D'Alessio, et al.
Tumori|September 27, 2022
Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic reviewAndrea Luciani, Antonio Ghidini, Karen Borgonovo, et al.
Pageof 40